Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00940225 · OUTCOME

Duration of Bone Scan Response - NRE Cohorts, CRPC Only

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From initial dose through final study visit up to 15 months

What was measured

The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.

Groups in this outcome

NRE Cohort - CRPC 100 mg

cabozantinib, 100 milligrams po QD for 12 weeks until progression or unacceptable toxicity.

NRE Cohort - CRPC 39.4 mg

cabozantinib, 39.4 milligrams po QD for 12 weeks until progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NRE Cohort - CRPC 100 mg69
NRE Cohort - CRPC 39.4 mg24

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
NRE Cohort - CRPC 100 mg5.2Not reported4.076.67Not reported
NRE Cohort - CRPC 39.4 mgNANot reportedNANAUnable to Estimate due to low numbers.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.07
        upper Limit
        6.67
        value
        5.2
      2. comment
        Unable to Estimate due to low numbers.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      69
    2. group Id
      OG001
      value
      24
    units
    Participants
description
The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.
dispersion Type
95% Confidence Interval
groups
  1. description
    cabozantinib, 100 milligrams po QD for 12 weeks until progression or unacceptable toxicity.
    id
    OG000
    title
    NRE Cohort - CRPC 100 mg
  2. description
    cabozantinib, 39.4 milligrams po QD for 12 weeks until progression or unacceptable toxicity.
    id
    OG001
    title
    NRE Cohort - CRPC 39.4 mg
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initial dose through final study visit up to 15 months
title
Duration of Bone Scan Response - NRE Cohorts, CRPC Only
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice